Shopping Cart 0
Cart Subtotal
USD 0

Neovacs SA (ALNEV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

Neovacs SA (Neovacs) is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF- kinoid and IFNalpha- kinoid products used for the treatment of rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus (SLE) or lupus. Its therapeutic vaccines use the patient's own immune system to generate the production of natural antibodies neutralizing the overproduced cytokines responsible for the disease. Neovacs' pipeline products portfolio includes VEGF-Kinoid for the treatment of age-related macular degeneration, solid tumors and IL4-Kinoid for the treatment of allergies. The company develops products using its proprietary kinoid technology that target cytokines for treatment of chronic autoimmune and inflammatory diseases. It conducts research and development activities on other high potential cytokine targets. Neovacs is headquartered in Paris, France.

Neovacs SA (ALNEV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neovacs SA, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11

Partnerships 12

Neovacs Enters into Agreement with Sunnybrook Research Institute 12

Stellar Biotech and Neovacs Form Joint Venture 13

Licensing Agreements 14

Centurion Pharma Enters into Licensing Agreement with Neovacs 14

BioSense Exercises Option for Licensing Agreement with Neovacs 15

Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16

Equity Offering 17

Neovacs Raises USD1.2 Million in Private Placement of Shares 17

Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18

Neovacs Raises USD4.1 Million in Issue of Shares 20

Neovacs Raises USD9 Million in Rights Offering of Shares 21

Neovacs Raises USD8.4 Million in Private placement of Shares 22

Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23

Neovacs Raises Funds in Private Placement of Shares 24

Neovacs to Raise USD8.8 Million in Private Placement of Shares 25

Neovacs Announces Private Placement Of 1.97 Million Shares 26

Neovacs Completes Rights Offering Of Shares For USD 11.4 Million 27

Debt Offering 28

Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28

Neovacs SA-Key Competitors 29

Neovacs SA-Key Employees 30

Neovacs SA-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 31

Recent Developments 32

Financial Announcements 32

Mar 30, 2018: Neovacs Provides Corporate Update and Reports Full-year 2017 Financial Results 32

Oct 27, 2017: Neovacs Provides Business Update and Announces Half-Year 2017 Financial Results 35

Mar 30, 2017: NEOVACS provides corporate update and reports full year 2016 financial results 37

Clinical Trials 39

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference 39

Feb 03, 2017: Neovacs Announces Independent Data and Safety Monitoring Board Supports Continuation of Phase IIb Clinical Trial for IFNa Kinoid in Lupus 40

Jan 25, 2017: Neovacs Reports First Positive Immunogenicity Results for IFNa Kinoid in Model of Type 1 Diabetes 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Neovacs SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Deals By Therapy Area, 2012 to YTD 2018 9

Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11

Neovacs Enters into Agreement with Sunnybrook Research Institute 12

Stellar Biotech and Neovacs Form Joint Venture 13

Centurion Pharma Enters into Licensing Agreement with Neovacs 14

BioSense Exercises Option for Licensing Agreement with Neovacs 15

Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16

Neovacs Raises USD1.2 Million in Private Placement of Shares 17

Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18

Neovacs Raises USD4.1 Million in Issue of Shares 20

Neovacs Raises USD9 Million in Rights Offering of Shares 21

Neovacs Raises USD8.4 Million in Private placement of Shares 22

Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23

Neovacs Raises Funds in Private Placement of Shares 24

Neovacs to Raise USD8.8 Million in Private Placement of Shares 25

Neovacs Announces Private Placement Of 1.97 Million Shares 26

Neovacs Completes Rights Offering Of Shares For USD 11.4 Million 27

Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28

Neovacs SA, Key Competitors 29

Neovacs SA, Key Employees 30

Neovacs SA, Subsidiaries 31

Neovacs SA, Joint Venture 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Neovacs SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Neovacs SA (Neovacs) is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF- kinoid and IFNalpha- kinoid products used for the treatment of rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus (SLE) or lupus. Its therapeutic vaccines use the patient's own immune system to generate the production of natural antibodies neutralizing the overproduced cytokines responsible for the disease. Neovacs' pipeline products portfolio includes VEGF-Kinoid for the treatment of age-related macular degeneration, solid tumors and IL4-Kinoid for the treatment of allergies. The company develops products using its proprietary kinoid technology that target cytokines for treatment of chronic autoimmune and inflammatory diseases. It conducts research and development activities on other high potential cytokine targets. Neovacs is headquartered in Paris, France.

Neovacs SA (ALNEV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neovacs SA, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11

Partnerships 12

Neovacs Enters into Agreement with Sunnybrook Research Institute 12

Stellar Biotech and Neovacs Form Joint Venture 13

Licensing Agreements 14

Centurion Pharma Enters into Licensing Agreement with Neovacs 14

BioSense Exercises Option for Licensing Agreement with Neovacs 15

Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16

Equity Offering 17

Neovacs Raises USD1.2 Million in Private Placement of Shares 17

Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18

Neovacs Raises USD4.1 Million in Issue of Shares 20

Neovacs Raises USD9 Million in Rights Offering of Shares 21

Neovacs Raises USD8.4 Million in Private placement of Shares 22

Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23

Neovacs Raises Funds in Private Placement of Shares 24

Neovacs to Raise USD8.8 Million in Private Placement of Shares 25

Neovacs Announces Private Placement Of 1.97 Million Shares 26

Neovacs Completes Rights Offering Of Shares For USD 11.4 Million 27

Debt Offering 28

Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28

Neovacs SA-Key Competitors 29

Neovacs SA-Key Employees 30

Neovacs SA-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 31

Recent Developments 32

Financial Announcements 32

Mar 30, 2018: Neovacs Provides Corporate Update and Reports Full-year 2017 Financial Results 32

Oct 27, 2017: Neovacs Provides Business Update and Announces Half-Year 2017 Financial Results 35

Mar 30, 2017: NEOVACS provides corporate update and reports full year 2016 financial results 37

Clinical Trials 39

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference 39

Feb 03, 2017: Neovacs Announces Independent Data and Safety Monitoring Board Supports Continuation of Phase IIb Clinical Trial for IFNa Kinoid in Lupus 40

Jan 25, 2017: Neovacs Reports First Positive Immunogenicity Results for IFNa Kinoid in Model of Type 1 Diabetes 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Neovacs SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Neovacs SA, Deals By Therapy Area, 2012 to YTD 2018 9

Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11

Neovacs Enters into Agreement with Sunnybrook Research Institute 12

Stellar Biotech and Neovacs Form Joint Venture 13

Centurion Pharma Enters into Licensing Agreement with Neovacs 14

BioSense Exercises Option for Licensing Agreement with Neovacs 15

Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16

Neovacs Raises USD1.2 Million in Private Placement of Shares 17

Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18

Neovacs Raises USD4.1 Million in Issue of Shares 20

Neovacs Raises USD9 Million in Rights Offering of Shares 21

Neovacs Raises USD8.4 Million in Private placement of Shares 22

Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23

Neovacs Raises Funds in Private Placement of Shares 24

Neovacs to Raise USD8.8 Million in Private Placement of Shares 25

Neovacs Announces Private Placement Of 1.97 Million Shares 26

Neovacs Completes Rights Offering Of Shares For USD 11.4 Million 27

Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28

Neovacs SA, Key Competitors 29

Neovacs SA, Key Employees 30

Neovacs SA, Subsidiaries 31

Neovacs SA, Joint Venture 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Neovacs SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.